| From: jmhollen | 6/16/2005 8:23:46 PM | | | | | | GenoMed Treats Its First Presumptive West Nile Virus Patient of 2005
Contact: David Moskowitz MD GenoMed, Inc. tel. 314-983-9933 dwmoskowitz@genomed.com
ST. LOUIS--June 16, 2005--GenoMed Inc.-- ("the Company" or "GenoMed") (National Quotation Bureau's Pink Sheets Symbol: GMED) a St. Louis, Missouri-based Next Generation Disease Management company, announced today that it has successfully treated its first patient this summer with presumed West Nile virus encephalitis.
The patient is a previously healthy 17 year old woman in Philadelphia, PA, whose parents called GenoMed yesterday from her hospital room. Their daughter had been agitated with a fever for three days. Bacterial meningitis had been ruled out by the hospital staff with a spinal tap. Her parents called GenoMed when she became delirious, and could no longer recognize them, despite being on antiviral medications. A family member had found out about GenoMed's clinical trial for West Nile virus on the Internet.
After two doses on GenoMed's protocol, 12 hours apart, the patient's mental state has improved markedly, according to her mother. She could recognize her parents, could tell her mother that she felt hot and thirsty, and has been sleeping quietly.
Said Dr. Moskowitz, GenoMed's CEO and Chief Medical Officer, "This patient's medical team diagnosed viral encephalitis. It will take a week or two to establish whether or not it's West Nile virus encephalitis. But since our treatment approach should work for most viruses, we could initiate treatment empirically. We're extremely gratified that her family turned to us, and even more excited that the patient has responded so quickly, as we've seen in previous summers."
The patient's doctors had told her parents to be prepared for her to remain delirious or in a coma for two to three weeks.
Physicians in Stanislaus County, California are now rushing GenoMed's WNV protocol to the local Institutional Review Board for use in their residents.
To enroll in GenoMed's trial, which uses already existing, safe medication present in every drug store and hospital, just go to www.genomed.com and click on the link for the West Nile virus trial.
About GenoMed
GenoMed has found what it believes to be the "master" disease gene, and has already been able to prevent kidney failure due to diabetes and hypertension in whites, blacks and Hispanics; dramatically delay the progression of terminal emphysema; and begin to see success in treating autoimmune diseases, West Nile virus encephalitis, and cancer. GenoMed's broad-spectrum anti-viral approach was specifically mentioned in BioShield II, recently introduced in the US Senate. GenoMed has recently found several thousand genes for the top six solid cancers in Caucasians--breast, colon, lung, ovarian, pancreatic, and prostate--and is currently offering its Healthchip(r) for early diagnosis of cancer on a research basis.
. |
| | GMED - GenoMed Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: jmhollen | 6/21/2005 3:29:39 PM | | | | | | GenoMed's Method to Prevent Most Kidney Dialysis Featured on IKIDNEY.COM
Contact: David Moskowitz MD GenoMed, Inc. tel. 314-983-9933 dwmoskowitz@genomed.com
ST. LOUIS--June 21, 2005--GenoMed Inc.-- ("the Company" or "GenoMed") (National Quotation Bureau's Pink Sheets Symbol: GMED) a St. Louis, Missouri-based Next Generation Disease Management company, announced today that its method to prevent up to 90% of kidney dialysis was featured in the latest version of NEPHROLOGY Incite, a newsletter for kidney patients at www.IKIDNEY.com.
Dr. David Moskowitz, GenoMed's CEO and Chief Medical Officer, was interviewed about his work on angiotensin I-converting enzyme (ACE). Said Dr. Moskowitz, "Using higher than usual doses of certain ACE inhibitors can actually reverse chronic kidney failure. But this approach must be started while a person's serum creatinine is below 2. A normal serum creatinine is less than 1.5. Patients aren't referred to a kidney specialist until their creatinine is close to 3. So it's imperative that patients learn about this before it's too late for them."
The full interview is at:
ikidney.com
About GenoMed
GenoMed has found what it believes to be the "master" disease gene, and has already been able to prevent kidney failure due to diabetes and hypertension in whites, blacks and Hispanics; dramatically delay the progression of terminal emphysema; and begin to see success in treating autoimmune diseases, West Nile virus encephalitis, and cancer. GenoMed's broad-spectrum anti-viral approach was specifically mentioned in BioShield II, recently introduced in the US Senate. GenoMed has recently found several thousand genes for the top six solid cancers in Caucasians--breast, colon, lung, ovarian, pancreatic, and prostate--and is currently offering its Healthchip(r) for early diagnosis of cancer on a research basis.
. |
| | GMED - GenoMed Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: jmhollen | 6/22/2005 9:48:47 AM | | | | | | GenoMed CEO Briefs AFL-CIO on How to Lower Healthcare Costs
Contact: David Moskowitz MD GenoMed, Inc. dwmoskowitz@genomed.com tel. 314-983-9933
ST. LOUIS--(June 22, 2005)--GenoMed Inc. ("the Company" or "GenoMed") (National Quotation Bureau's Pink Sheets Symbol GMED) announced today that its CEO, David Moskowitz MD, was invited to speak yesterday on lowering healthcare costs before the AFL-CIO Healthcare Taskforce at AFL-CIO headquarters in Washington, D.C.
Said Dr. Moskowitz, "Rising healthcare costs has been the number one labor issue for several years. It's possible that GM could reverse its recently announced layoffs if it found a way to lower its healthcare bill. Fortunately, GenoMed's cutting-edge medicine and cheaper drugs can save 10% of healthcare costs immediately and for years to come."
Added Dr. Moskowitz, "This message, I hope, will also be heard by our nation's fifty state Medicaid programs, which are all in the same boat. The solution some states have taken, like Tennessee and my own state of Missouri, is to simply disenroll hundreds of thousands of Medicaid recipients in order to make ends meet. Rather than cutting these people loose to die, I hope state legislators can follow the AFL-CIO's lead and learn about other options to save money. Clearly, we as a society can no longer afford to ignore 21st century preventive molecular medicine."
. |
| | GMED - GenoMed Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: jmhollen | 6/24/2005 2:52:04 PM | | | | | | GenoMed's WNV Treatment Abruptly Stopped, Patient Deteriorates
Contact: David W. Moskowitz MD FACP GenoMed, Inc. Tel. 314.983.9933
PHILADELPHIA, PA.--June 24, 2005--GenoMed (the "Company") (Pink Sheets GMED), a Next Generation DM(tm) company that uses molecular medicine to improve patient outcomes and save healthcare costs, announced today that its first presumed West Nile virus encephalitis patient is doing poorly after GenoMed's treatment was abruptly stopped last week.
The patient received two doses of GenoMed's treatment for WNV on Wednesday and early Thursday morning last week, and appeared to get better according to her mother (see 6/16/05 press release). When she was moved to the Intensive Care Unit for closer monitoring, her new Attending Physician could not be convinced of the usefulness of GenoMed's treatment, and stopped it. She has been without GenoMed's treatment for over a week now.
Said Dr. David Moskowitz, GenoMed's CEO and Chief Medical Officer, "I happened to be in Philadelphia this week for a Disease Management conference, and visited the patient in the ICU on Wednesday evening. She had evidence of decorticate posturing then, constantly shrugging her shoulders inwards. She was unresponsive to pain or verbal stimuli. The situation looked grim."
Added Dr. Moskowitz, "We will never know in this poor patient's case what would have happened if she had just stayed on our treatment. Perhaps she would be exactly as sick as she is now. But it looked like she was getting better, as eleven out of fourteen of our patients have done the past two summers. Now she has full-blown viral encephalitis, and the eventual outcome does not look good. "
The patient's initial serum test for West Nile virus was negative, as is usually the case, so she has not yet been reported to the health authorities. A convalescent serum titer will be drawn in several weeks to see if she has WNV.
ABOUT GENOMED
GenoMed is a Next Generation DM(tm) [Disease Management] company that uses molecular medicine to improve patient outcomes and thus lower healthcare costs. Although the Company has effective treatments, there are obstacles to their adoption, as illustrated by this example. Currently, the company is marketing its protocols for preventing kidney failure from diabetes and high blood pressure, and significantly delaying emphysema.
GenoMed is conducting a free trial for WNV for the third consecutive summer. Those interested in participating are invited to download the trial documents from the Company's home page at www.genomed.com
. |
| | GMED - GenoMed Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: jmhollen | 6/29/2005 10:00:39 AM | | | | | | GenoMed CEO Testifies Before Missouri Medicaid Reform Commission
Contact: David Moskowitz MD FACP GenoMed, Inc. dwmoskowitz@genomed.com tel. 314-983-9933
ST. LOUIS--(June 29, 2005)--GenoMed Inc. ("the Company" or "GenoMed") (National Quotation Bureau's Pink Sheets Symbol GMED) announced today that its CEO, David Moskowitz MD, has been invited to testify today, the first day of public testimony, before the Missouri Medicaid Reform Commission. The Medicaid Reform Commission is a joint committee of the Missouri House and Senate empanelled to study ways to rein in rising healthcare costs for the Missouri state Medicaid program.
As a first attempt, the Missouri Legislature cut 65,000 patients from the state Medicaid program this spring. These patients lose coverage on July 1st, i.e. this Friday. Since oxygen tanks are among the items no longer covered, many patients will soon die.
Said Dr. Moskowitz, "I'm honored to represent GenoMed and the promise of genomics-based medicine at the very first session of public testimony before the Missouri Medicaid Reform Commission. I'm happy to describe the dramatic cost-savings that Next Generation Disease Management can yield, as I did last week for the AFL-CIO Healthcare Taskforce in Washington, DC. My earnest hope is that Missouri legislators will consider adopting our protocols and stop the disenrollments before a single patient has died."
Added Dr. Moskowitz, "The Missouri Legislature is wrestling with the most critical domestic issue of our time. It is literally a life and death issue for tens of millions of Americans. It seems to me profoundly un-American, on the eve of our nation's birthday, to have people die simply because Medicaid is still paying retail for drugs. The best way to control healthcare costs is to control diseases and cut back on hospitalizations. Only genomics-based medicine can do this. And only GenoMed has demonstrated that it can halt cardiovascular diseases including emphysema."
About GenoMed
GenoMed, Inc. is a Next Generation DM(TM) company whose mission is to improve patient outcomes by identifying the molecular pathways that cause disease. DM (Disease Management) is the only healthcare player whose business model is to profit by lowering healthcare costs. A St. Louis Business Journal article (http://www.stlouis.bizjournals.com/stlouis/stories/2002/05/13/story8.html) first reported that the company applied for patents based on its finding that the ACE gene is associated with many common diseases. The company is currently marketing its protocols for preventing kidney failure due to diabetes and high blood pressure, and delaying the progression of emphysema.
. |
| | GMED - GenoMed Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: jmhollen | 7/13/2005 10:36:22 AM | | | | | | GenoMed Joins International Disease Management Alliance
ST. LOUIS--(July 13, 2005)--GenoMed Inc. ("the Company" or "GenoMed") (National Quotation Bureau's Pink Sheets Symbol GMED) announced today that it has joined the International Disease Management Alliance (IDMA) recently organized by Warren E. Todd, the group's founder and Executive Director.
The IDMA (www.dmalliance.org) was formed to promote the concept of Disease Management around the world. As the only healthcare strategy that both improves patient outcomes and reduces healthcare costs, Disease Management has as much appeal globally as it does in the United States.
Said Warren E. Todd, Executive Director for IDMA, "We're delighted to welcome GenoMed to the Alliance and applaud their recognition of the international potential for disease management . Genomics provides a differentiated approach to disease management that should be well received in countries where more physician-centric models of disease management are common."
GenoMed's CEO, David Moskowitz MD, said, "We are thrilled to be one of the first Institutional members of the new IDMA and look forward to supporting the global expansion. Warren Todd is famous as one of the founders of the Disease Management industry in the U.S., and now around the world. We've long believed that our Next Generation DM(tm) business model would resonate especially well with capitated health plans, such as National Health Services in Canada, Europe, Japan, the United Kingdom, and other Commonwealth countries. GenoMed's membership in the IDMA should provide us with an entree to the global healthcare market. Our reliance on the Internet rather than telephone call centers, and our novel physician-oriented business model, give us a global reach immediately."
Added Dr. Moskowitz, "Rising healthcare costs have already reached a crisis point in the U.S. Medicaid programs in many states have begun disenrolling patients to lower costs. Many of these patients will soon die for lack of medications. The best way to control healthcare costs is to control diseases and cut back on hospitalizations. Only genomics-based medicine can do this. And only GenoMed has demonstrated that it can halt cardiovascular diseases including emphysema."
About GenoMed
GenoMed, Inc. is a Next Generation DM(TM) company whose mission is to improve patient outcomes by identifying the molecular pathways that cause disease. A St. Louis Business Journal article (http://www.stlouis.bizjournals.com/stlouis/stories/2002/05/13/story8.html) first reported that the company applied for patents based on its finding that the ACE gene is associated with many common diseases. The company is currently marketing its protocols for preventing kidney failure due to diabetes and high blood pressure, and delaying the progression of emphysema.
Contact:
David Moskowitz MD FACP
GenoMed, Inc.
dwmoskowitz@genomed.com
tel. 314-983-9933
. |
| | GMED - GenoMed Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: jmhollen who wrote (271) | 7/27/2005 2:46:56 PM | | From: Tadsamillionaire | | | | GenoMed Submits 50th Provisional Patent
ST. LOUIS, July 26 /PRNewswire-FirstCall/ -- GenoMed Inc. ('the Company' or 'GenoMed') (Pink Sheets: GMED) announced today that the Company has submitted its 50th provisional patent application, a major milestone in any development stage company. GenoMed has so far been awarded two patents, one for treating acute kidney failure without dialysis, and another for hastening lung maturation in prematurely born infants.
Two of the most recently submitted patent applications include a drug delivery system whereby the delivery of drugs to the bloodstream is controlled through specially formulated toothpastes, and a method to reduce scarring and fibrosis both on the skin and in internal organs.
Small proteins like insulin don't survive the strong acid environment of the stomach, and must be injected to get into the bloodstream. As a result, patients with diabetes have to inject themselves under the skin one to three times a day. Putting insulin in toothpaste may be an effective method to get insulin into the bloodstream directly, especially after flossing, which often causes bleeding of the gums. It may be especially useful for patients with juvenile-onset diabetes, who must begin injecting insulin as pre-teens.
GenoMed's method to reduce scarring, both on the skin and in internal organs, involves another novel use for angiotensin I-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) either as pills, which already exist, or as topical creams. This approach may be useful in dermatology and plastic surgery, especially for burn victims who get extensive scarring, patients with keloid scars, etc.
GenoMed is currently looking for partners to help develop its toothpaste drug delivery system, as well as patients with scars or fibrosis of internal organs for clinical trials. Please contact GenoMed's CEO and Chief Medical Officer, David Moskowitz MD, at dwmoskowitz@genomed.com. |
| | GMED - GenoMed Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| From: jmhollen | 8/22/2005 4:06:22 PM | | | | | | GenoMed Adds Dr. Richard Reece to Business Development Advisory Board
FOR IMMEDIATE RELEASE
Contact:
David Moskowitz MD FACP
GenoMed, Inc.
dwmoskowitz@genomed.com
tel. 314-983-9933
ST. LOUIS--(August 22, 2005)--GenoMed Inc. ("the Company" or "GenoMed") (National Quotation Bureau's Pink Sheets symbol GMED) announced today the addition of Dr. Richard Reece, a prolific and influential medical writer, to its Business Development Advisory Board.
Dr. Richard Reece is a pathologist, writer, editor, and author. He has served as editor-in-chief of Physician Practice Options, a monthly newsletter for practicing physicians for nine years. The newsletter has variations that reach cardiologists, nephrologists, and oncologists. He is the author of four books. The latest is Voices of Health Reform (Practice Support Resources, Inc, 2005) consisting of 41 interviews with leading health care authorities. He also writes frequently for Healthleaders.com, which is read by 50,000 health care leaders each day. He serves on the advisory boards of the Center for Practical Health Reform and America's Top Doctors, a 1300 page book listings America's top doctors, based on nominations of other doctors.
Said Dr. David Moskowitz, GenoMed's Chairman and CEO, "Dr. Reece is a leader in developing practical approaches to health care reform, including consumer-directed healthcare. We are honored to have his help in crafting and delivering GenoMed's message of cost control and quality improvement to medical societies, health plans, and business coalitions."
About GenoMedTM
GenoMed, Inc. is a Next Generation DMTM company whose mission is to improve patient outcomes by identifying the molecular pathways or genes that cause disease. A St. Louis Business Journal article (http://www.stlouis.bizjournals.com/stlouis/stories/2002/05/13/story8.html) first reported that the company applied for patents based on its finding that the ACE gene is associated with many common diseases. The company is currently marketing its protocols for preventing kidney failure due to diabetes and high blood pressure, and delaying the progression of emphysema. The company is also conducting a free clinical trial for West Nile virus; to enroll, simply click on the West Nile virus link at www.genomed.com
. |
| | GMED - GenoMed Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: jmhollen | 8/24/2005 7:01:06 PM | | | | | | GenoMed™ Adds IT Experts to Business Development Advisory Board
Contact: David Moskowitz MD FACP GenoMed, Inc. dwmoskowitz@genomed.com tel. 314-983-9933
ST. LOUIS--(August 24, 2005)--GenoMed Inc. ("the Company" or "GenoMed") (National Quotation Bureau's Pink Sheets symbol GMED) today announced the addition of IT experts Jack Gruninger and Chris Todd to its Business Development Advisory Board.
Jack Gruninger has over 15 years of experience in leading advanced Information Technology projects in the commercial and government sectors. He is currently Vice President – Technology for L-3 Communications Titan Corporation, founder of TapHere! Technology LLC, member of the Technology Advisory Board for the International Disease Management Association, and previously served as CTO for Brainbench.com.
Mr. Gruninger has provided technical presentations for many industry-leading technology conferences/seminars including the International Sybase Users Group, Professional Association for SQL Server, US Armed Forces Decision AIDS Conference, Armed Forces Communications & Electronics Association, and the Global Command & Control System Functional Working Group.
Chris Todd currently serves as Senior Software Engineer at L-3 Communications Titan Corporation, Vice President – Multimedia for TapHere! Technology LLC, and is a member of the Technology Advisory Board for the International Disease Management Association.
Mr. Todd has been a pioneer in commercial web technology and has extensive experience with leading-edge software/hardware design, database development, object-oriented programming, Internet / networking operations, optics, and multimedia. He has designed and developed over 30 enterprise-class, multi-tier software applications, many of which are deployed for operations and collaboration among leading health care organizations.
Said Dr. David Moskowitz, GenoMed's Chairman and CEO, "Our business relies entirely on the World Wide Web. Jack Gruninger and Chris Todd are experts in designing websites, adding multimedia content—video and audio--to websites, and making websites easy to find by search engines. To increase our revenue stream, we need a website that's easy for America's 80 million patients with diabetes and high blood pressure, and 5 million patients with emphysema, to find—not to mention the hundreds of millions of patients with these diseases worldwide."
About GenoMed™
GenoMed, Inc. is a Next Generation DM™ company whose mission is to improve patient outcomes by identifying the molecular pathways that cause disease. The company is currently marketing its protocols for preventing kidney failure due to diabetes and high blood pressure, and delaying the progression of emphysema. The company is also conducting a free clinical trial for West Nile virus; to enroll, simply click on the West Nile virus link at www.genomed.com
. |
| | GMED - GenoMed Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| |
